A phase I, placebo controlled, dose escalation safety and pharmacokinetic study of (Z)-Endoxifen in healthy female volunteers
Phase of Trial: Phase I
Latest Information Update: 25 Sep 2017
At a glance
- Drugs Endoxifen (Primary) ; Endoxifen (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Atossa Genetics
- 25 Sep 2017 Preliminary results published in an Atossa Genetics Media Release
- 18 Sep 2017 Status changed from active, no longer recruiting to completed.
- 14 Sep 2017 According to an Atossa Genetics media release, results from the oral arm is expected in the next 30-60 days.